Intorio, Corp., soon to be renamed REDOX International Group, has released its Form 10-Q report, detailing the company's financial and operational performance for the three months ended May 31, 2024. Intorio, Corp. focuses on functional medicine and health management services, operating through several entities including REDOX Biomedicine Co., Ltd, REDOX Functional Medicine Laboratory, REDOX Integrative and Functional Medicine Center, and the Chinese Functional Medicine Association.
Financial Highlights
- Revenues: $0. The company did not generate any revenue during the three months ended May 31, 2024.
- Operating Income (Loss): $(921). The operating loss for the period was primarily due to general and administrative expenses.
- Net Income (Loss) for the Period: $(1,918). The net loss includes a loss from the disposition of assets amounting to $997.
- Net income per share: Basic and diluted: $0. There was no net income per share as the company reported a net loss.
Business Highlights
- Business Description: Intorio, Corp. focuses on functional medicine and health management services through several entities including REDOX Biomedicine Co., Ltd, REDOX Functional Medicine Laboratory, REDOX Integrative and Functional Medicine Center, and the Chinese Functional Medicine Association.
- Recent Developments: On May 16, 2024, a significant change in ownership occurred with the sale of 2,000,000 shares to six accredited investors, leading to a change in control. Dr. Han-Wen Ou was appointed as the new CEO and Director.
- Operational Focus: The company is dedicated to advancing functional medicine in Asia, with a focus on longevity medicine, metabolic resilience, and whole-person care. It has established a leading functional medicine laboratory in Asia and is involved in promoting functional medicine concepts internationally.
- Future Outlook: The company plans to enhance its operational capabilities by increasing working capital through a combination of existing funds and further issuances of securities. It anticipates additional increases in operating expenses and capital expenditures related to inventory acquisition, developmental expenses, and marketing.
- Functional Medicine Services: REDOX offers a range of functional medicine laboratory testing services, including metabolic disease risk prevention, hormone concentration analysis, nutritional status assessment, environmental toxin exposure evaluation, immune system stability testing, gastrointestinal function analysis, and genetic analysis for disease prevention.
- Leadership and Expertise: Dr. Han-Wen Ou brings extensive experience in functional medicine and clinical nutrition, having held positions such as Director of The American Academy of Anti-Aging Medicine in Taiwan, China, and Singapore.
SEC Filing: